Data from the SURMOUNT-3 trial, presented at Obesity Week 2023, showed that use of tirzepatide (Mounjaro) led to an additional…
Data from the SURMOUNT-3 trial, presented at Obesity Week 2023, showed that use of tirzepatide (Mounjaro) led to an additional…
Login below or Register Now.
Already registered? Login.